- Home
- TRMD vs SRPT Comparison
TRMD vs SRPT Comparison
Compare TRMD & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | SRPT |
|---|---|---|
| Founded | 1889 | 1980 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TRMD | SRPT |
|---|---|---|
| Price | $31.87 | $16.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 29 |
| Target Price | ★ $35.00 | $25.85 |
| AVG Volume (30 Days) | 820.4K | ★ 2.7M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ $5.78 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $15.79 | $10.42 |
| 52 Week High | $35.33 | $43.92 |
Technical Indicators
Market Signals| Indicator | TRMD | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 29.88 |
| Support Level | $29.15 | $16.09 |
| Resistance Level | $31.76 | $19.32 |
| Average True Range (ATR) | 1.15 | 1.13 |
| MACD | -0.32 | -0.52 |
| Stochastic Oscillator | 15.53 | 0.72 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.